Geron Corporation (NASDAQ:GERN) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET

Company Participants

Aron Feingold - Vice President of IR and Corporate Communication
John Scarlett - Chairman and CEO
Jim Ziegler - EVP and CCO
Michelle Robertson - EVP and CFO
Faye Feller - EVP, CMO
Andrew Grethlein - EVP, COO

Conference Call Participants

Tara Bancroft - T. D. Cowen
Faisal Khurshid - Leerink Partners
Corinne Johnson - Goldman Sachs
Carter Gould - Barclays
Emily Bodnar - H.C. Wainwright
Stephen Willey - Stifel
Kalpit Patel - B. Riley Securities
Gil Blum - Needham & Company

Operator

Hello, and welcome to the Geron Corporation Third Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions].

I would now like to turn the conference over to Aron Feingold, Vice President of Investor Relations and Corporate Communication. You may begin.

Aron Feingold

Good morning, everyone. Welcome to the Geron Corporation third quarter 2024 earnings conference call. I am Aron Feingold, Geron's Vice President of Investor Relations and Corporate Communication.

I'm joined today by several members of Geron's management team. Dr. John Scarlett, Chairman and Chief Executive Officer; Michelle Robertson, Executive Vice President and Chief Financial Officer; Jim Ziegler, Executive Vice President and Chief Commercial Officer; Dr. Faye Feller, Executive Vice President, Chief Medical Officer; and Dr. Andrew Grethlein, Executive Vice President, Chief Operating Officer.

Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations and other projections, including those relating to the launch, commercial opportunity and therapeutic potential of RYTELO, anticipated clinical and commercial events and related timelines, the sufficiency of Geron's financial resources and other statements that are not historical facts.

Actual events or results could differ materially. Therefore, I refer you to the discussion under the heading Risk Factors in Geron's most recent periodic report filed with the SEC, which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements and our future updates to those risk factors. Geron undertakes no duty or obligation to update our forward-looking statements.

With that, I'll turn the call over to Chip. Chip?

John Scarlett

Thanks, Aaron. Good morning to everybody on the call. Thanks for joining us today. Following FDA approval and the commercial launch of RYTELO, our first-in-class telomerase inhibitor, this has been a transformative year for Geron. As a result, we believe we're well-positioned to build long-term commercial value with this product.